English

AERIE PHARMACEUTICALS INC

EDGAR

AERI Quarterly report (10-Q) · filed 2022-11-04

174 filing records in this dataset, filed from 2013-09-17 to 2022-11-04. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

36.1 million USD

2022 Q3 · USD

Exact inputs and evidence

Revenue: 36129000 USD Source

Operating margin

-73.82%

2022 Q3 · %

Exact inputs and evidence

Operating Income: -26672000 USD Source
Revenue: 36129000 USD Source

Operating cash flow

-11.4 million USD

2022 Q3 · USD

Exact inputs and evidence

Operating Cash Flow: 37277000 USD Source
Operating Cash Flow: 48678000 USD Source

Free cash flow

-12.2 million USD

2022 Q3 · USD

Exact inputs and evidence

Operating Cash Flow: 37277000 USD Source
Operating Cash Flow: 48678000 USD Source
Capital Expenditure: 3779000 USD Source
Capital Expenditure: 2966000 USD Source

Cash and cash equivalents: 54.1 million USD 2022-09-30 Source
Exact value

54093000 USD
Long-term debt including current maturities: 0 USD 2013-12-31 Source
Exact value

0 USD
Shares outstanding: 49.4 million shares 2022-09-30 Source
Exact value

49390503 shares

Reported share-count change

4.69% · 2.21 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

47179733 shares · 2021-09-30· Source
49390503 shares · 2022-09-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

214 million USD

2021-10-01 – 2022-09-30

Exact inputs and evidence

Revenue: 194134000 USD · 2021-01-01 – 2021-12-31 Source
Revenue: 79468000 USD · 2021-01-01 – 2021-09-30 Source
Revenue: 29835000 USD · 2022-01-01 – 2022-03-31 Source
Revenue: 33311000 USD · 2022-04-01 – 2022-06-30 Source
Revenue: 36129000 USD · 2022-07-01 – 2022-09-30 Source

Net income

-36.6 million USD

2021-10-01 – 2022-09-30

Exact inputs and evidence

Net income: -74810000 USD · 2021-01-01 – 2021-12-31 Source
Net income: -120343000 USD · 2021-01-01 – 2021-09-30 Source
Net income: -35891000 USD · 2022-01-01 – 2022-03-31 Source
Net income: -19371000 USD · 2022-04-01 – 2022-06-30 Source
Net income: -26826000 USD · 2022-07-01 – 2022-09-30 Source

Operating cash flow

7.17 million USD

2021-10-01 – 2022-09-30

Exact inputs and evidence

Operating cash flow: -99154000 USD · 2021-01-01 – 2021-12-31 Source
Operating cash flow: -69044000 USD · 2021-01-01 – 2021-09-30 Source
Operating cash flow: 61911000 USD · 2022-01-01 – 2022-03-31 Source
Operating cash flow: 48678000 USD · 2022-01-01 – 2022-06-30 Source
Operating cash flow: 61911000 USD · 2022-01-01 – 2022-03-31 Source
Operating cash flow: 37277000 USD · 2022-01-01 – 2022-09-30 Source
Operating cash flow: 48678000 USD · 2022-01-01 – 2022-06-30 Source

Capital expenditure

4.53 million USD

2021-10-01 – 2022-09-30

Exact inputs and evidence

Capital expenditure: 3291000 USD · 2021-01-01 – 2021-12-31 Source
Capital expenditure: 2540000 USD · 2021-01-01 – 2021-09-30 Source
Capital expenditure: 1597000 USD · 2022-01-01 – 2022-03-31 Source
Capital expenditure: 2966000 USD · 2022-01-01 – 2022-06-30 Source
Capital expenditure: 1597000 USD · 2022-01-01 – 2022-03-31 Source
Capital expenditure: 3779000 USD · 2022-01-01 – 2022-09-30 Source
Capital expenditure: 2966000 USD · 2022-01-01 – 2022-06-30 Source

Free cash flow

2.64 million USD

2021-10-01 – 2022-09-30

Exact inputs and evidence

Operating cash flow: -99154000 USD · 2021-01-01 – 2021-12-31 Source
Operating cash flow: -69044000 USD · 2021-01-01 – 2021-09-30 Source
Operating cash flow: 61911000 USD · 2022-01-01 – 2022-03-31 Source
Operating cash flow: 48678000 USD · 2022-01-01 – 2022-06-30 Source
Operating cash flow: 61911000 USD · 2022-01-01 – 2022-03-31 Source
Operating cash flow: 37277000 USD · 2022-01-01 – 2022-09-30 Source
Operating cash flow: 48678000 USD · 2022-01-01 – 2022-06-30 Source
Capital expenditure: 3291000 USD · 2021-01-01 – 2021-12-31 Source
Capital expenditure: 2540000 USD · 2021-01-01 – 2021-09-30 Source
Capital expenditure: 1597000 USD · 2022-01-01 – 2022-03-31 Source
Capital expenditure: 2966000 USD · 2022-01-01 – 2022-06-30 Source
Capital expenditure: 1597000 USD · 2022-01-01 – 2022-03-31 Source
Capital expenditure: 3779000 USD · 2022-01-01 – 2022-09-30 Source
Capital expenditure: 2966000 USD · 2022-01-01 – 2022-06-30 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2022-11-04.

Financial data available through: 2021-12-31.

Coverage by financial measure

Revenue: 6 of 11 periods available· newest 2021-12-31
Operating income: 11 of 11 periods available· newest 2021-12-31
Net income: 11 of 11 periods available· newest 2021-12-31
Operating cash flow: 11 of 11 periods available· newest 2021-12-31
Capital expenditure: 11 of 11 periods available· newest 2021-12-31
Total assets: 6 of 11 periods available· newest 2021-12-31
Total liabilities: 6 of 11 periods available· newest 2021-12-31
Current assets: 6 of 11 periods available· newest 2021-12-31
Current liabilities: 6 of 11 periods available· newest 2021-12-31
Cash and cash equivalents: 6 of 11 periods available· newest 2021-12-31
long term debt: No compatible figures in this window
Shares outstanding: 6 of 11 periods available· newest 2021-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+133.5%

Prior period

USD 83.14 million

2020-01-01 – 2020-12-31
Current period

USD 194.13 million

2021-01-01 – 2021-12-31

Exact inputs and evidence

194134000 − 83138000 = 110996000 USD

83138000 USD · 2020-01-01 – 2020-12-31
Inspect prior input Prior source
194134000 USD · 2021-01-01 – 2021-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · AERIE PHARMACEUTICALS INC · 2021-12-31 AERIE PHARMACEUTICALS INC (edgar:1337553) Year-over-year change in Revenue: 110996000 USD Concept: fundies:Revenue Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1337553?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 194134000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1337553/000133755322000013/aeri-20211231.htm#1579275 Filing: 000133755322000013 Input fundies:Revenue: 83138000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1337553/000133755322000013/aeri-20211231.htm#1580325 Filing: 000133755322000013
The citation records this snapshot. The page link may show a newer release later.
Net income
+USD 108.29 million

Prior period

−USD 183.1 million

2020-01-01 – 2020-12-31
Current period

−USD 74.81 million

2021-01-01 – 2021-12-31

Exact inputs and evidence

-74810000 − -183101000 = 108291000 USD

-183101000 USD · 2020-01-01 – 2020-12-31
Inspect prior input Prior source
-74810000 USD · 2021-01-01 – 2021-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · AERIE PHARMACEUTICALS INC · 2021-12-31 AERIE PHARMACEUTICALS INC (edgar:1337553) Year-over-year change in Net income: 108291000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1337553?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -74810000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1337553/000133755322000013/aeri-20211231.htm#1764693 Filing: 000133755322000013 Input fundies:NetIncome: -183101000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1337553/000133755322000013/aeri-20211231.htm#1766408 Filing: 000133755322000013
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 34.46 million

Prior period

−USD 64.69 million

2020-01-01 – 2020-12-31
Current period

−USD 99.15 million

2021-01-01 – 2021-12-31

Exact inputs and evidence

-99154000 − -64690000 = -34464000 USD

-64690000 USD · 2020-01-01 – 2020-12-31
Inspect prior input Prior source
-99154000 USD · 2021-01-01 – 2021-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · AERIE PHARMACEUTICALS INC · 2021-12-31 AERIE PHARMACEUTICALS INC (edgar:1337553) Year-over-year change in Operating cash flow: -34464000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1337553?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -99154000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1337553/000133755322000013/aeri-20211231.htm#1808560 Filing: 000133755322000013 Input fundies:OperatingCashFlow: -64690000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1337553/000133755322000013/aeri-20211231.htm#1809611 Filing: 000133755322000013
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+6.2%

Prior period

USD 3.1 million

2020-01-01 – 2020-12-31
Current period

USD 3.29 million

2021-01-01 – 2021-12-31

Exact inputs and evidence

3291000 − 3100000 = 191000 USD

3100000 USD · 2020-01-01 – 2020-12-31
Inspect prior input Prior source
3291000 USD · 2021-01-01 – 2021-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · AERIE PHARMACEUTICALS INC · 2021-12-31 AERIE PHARMACEUTICALS INC (edgar:1337553) Year-over-year change in Capital expenditure: 191000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1337553?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 3291000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1337553/000133755322000013/aeri-20211231.htm#1822011 Filing: 000133755322000013 Input fundies:CapitalExpenditure: 3100000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1337553/000133755322000013/aeri-20211231.htm#1822994 Filing: 000133755322000013
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2021 2021-01-01 – 2021-12-31

Revenue USD 194.13 million 100% of revenue
Cost of revenue USD 26.85 million 14% of revenue
Operating expenses USD 213.64 million 110% of revenue
Operating income −USD 46.35 million −24% of revenue
Tax, interest and other Derived USD 28.46 million 15% of revenue
Net income −USD 74.81 million −39% of revenue

Cash

Operating cash flow −USD 99.15 million −51% of revenue
Capital expenditure USD 3.29 million 1.7% of revenue
Free cash flow Derived −USD 102.45 million −53% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2016 Not shown: operating income or net income is not reported.
2017 Not shown: operating income or net income is not reported.
2018 Operating loss: operating costs were 967% of revenue.
2019 Operating loss: operating costs were 368% of revenue.
2020 Operating loss: operating costs were 287% of revenue.
2021 Operating loss: operating costs were 124% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2016 2016-01-01 – 2016-12-31	0	96872000 Derived	-96872000	2187000 Derived	-99059000	-84917000 Derived	Source 2016-01-01 – 2016-12-31: 0 USD Inspect Revenue Open source 2016-01-01 – 2016-12-31: -96872000 USD Inspect Operating Income Open source 2016-01-01 – 2016-12-31: -99059000 USD Inspect Net Income Open source 2016-01-01 – 2016-12-31: -79840000 USD Inspect Operating Cash Flow Open source 2016-01-01 – 2016-12-31: 5077000 USD Inspect Capital Expenditure Open source
2017 2017-01-01 – 2017-12-31	0	145693000 Derived	-145693000	-588000 Derived	-145105000	-109183000 Derived	Source 2017-01-01 – 2017-12-31: 0 USD Inspect Revenue Open source 2017-01-01 – 2017-12-31: -145693000 USD Inspect Operating Income Open source 2017-01-01 – 2017-12-31: -145105000 USD Inspect Net Income Open source 2017-01-01 – 2017-12-31: -93213000 USD Inspect Operating Cash Flow Open source 2017-01-01 – 2017-12-31: 15970000 USD Inspect Capital Expenditure Open source
2018 2018-01-01 – 2018-12-31	24181000	233923000 Derived	-209742000	22827000 Derived	-232569000	-183889000 Derived	Source 2018-01-01 – 2018-12-31: 24181000 USD Inspect Revenue Open source 2018-01-01 – 2018-12-31: -209742000 USD Inspect Operating Income Open source 2018-01-01 – 2018-12-31: -232569000 USD Inspect Net Income Open source 2018-01-01 – 2018-12-31: -152576000 USD Inspect Operating Cash Flow Open source 2018-01-01 – 2018-12-31: 31313000 USD Inspect Capital Expenditure Open source
2019 2019-01-01 – 2019-12-31	69888000	257380000 Derived	-187492000	12089000 Derived	-199581000	-160388000 Derived	Source 2019-01-01 – 2019-12-31: 69888000 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: -187492000 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: -199581000 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: -150430000 USD Inspect Operating Cash Flow Open source 2019-01-01 – 2019-12-31: 9958000 USD Inspect Capital Expenditure Open source
2020 2020-01-01 – 2020-12-31	83138000	238828000 Derived	-155690000	27411000 Derived	-183101000	-67790000 Derived	Source 2020-01-01 – 2020-12-31: 83138000 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -155690000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -183101000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -64690000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 3100000 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	194134000	240488000 Derived	-46354000	28456000 Derived	-74810000	-102445000 Derived	Source 2021-01-01 – 2021-12-31: 194134000 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -46354000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -74810000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -99154000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 3291000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 194.1M 2021

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Revenue	0	Revenue: 0 Open source
20172017-12-31	Revenue	0	Revenue: 0 Open source
20182018-12-31	Revenue	24181000	Revenue: 24181000 Open source
20192019-12-31	Revenue	69888000	Revenue: 69888000 Open source
20202020-12-31	Revenue	83138000	Revenue: 83138000 Open source
20212021-12-31	Revenue	194134000	Revenue: 194134000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

133.5% 2021

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Year over year	No prior comparable period	Revenue: 0 Open source
20172017-12-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source
20182018-12-31	Year over year	No prior comparable period	Revenue: 24181000 Open source Revenue: 0 Open source
20192019-12-31	Year over year	189%	Revenue: 69888000 Open source Revenue: 24181000 Open source
20202020-12-31	Year over year	19%	Revenue: 83138000 Open source Revenue: 69888000 Open source
20212021-12-31	Year over year	133.5%	Revenue: 194134000 Open source Revenue: 83138000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -23.9% 2021

Net margin -38.5% 2021

Free cash flow margin -52.8% 2021

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Operating margin	Not reported	Operating Income: -96872000 Open source Revenue: 0 Open source
20172017-12-31	Operating margin	Not reported	Operating Income: -145693000 Open source Revenue: 0 Open source
20182018-12-31	Operating margin	-867.4%	Operating Income: -209742000 Open source Revenue: 24181000 Open source
20192019-12-31	Operating margin	-268.3%	Operating Income: -187492000 Open source Revenue: 69888000 Open source
20202020-12-31	Operating margin	-187.3%	Operating Income: -155690000 Open source Revenue: 83138000 Open source
20212021-12-31	Operating margin	-23.9%	Operating Income: -46354000 Open source Revenue: 194134000 Open source
20162016-12-31	Net margin	Not reported	Net Income: -99059000 Open source Revenue: 0 Open source
20172017-12-31	Net margin	Not reported	Net Income: -145105000 Open source Revenue: 0 Open source
20182018-12-31	Net margin	-961.8%	Net Income: -232569000 Open source Revenue: 24181000 Open source
20192019-12-31	Net margin	-285.6%	Net Income: -199581000 Open source Revenue: 69888000 Open source
20202020-12-31	Net margin	-220.2%	Net Income: -183101000 Open source Revenue: 83138000 Open source
20212021-12-31	Net margin	-38.5%	Net Income: -74810000 Open source Revenue: 194134000 Open source
20162016-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -79840000 Open source Capital Expenditure: 5077000 Open source
20172017-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -93213000 Open source Capital Expenditure: 15970000 Open source
20182018-12-31	Free cash flow margin	-760.5%	Revenue: 24181000 Open source Operating Cash Flow: -152576000 Open source Capital Expenditure: 31313000 Open source
20192019-12-31	Free cash flow margin	-229.5%	Revenue: 69888000 Open source Operating Cash Flow: -150430000 Open source Capital Expenditure: 9958000 Open source
20202020-12-31	Free cash flow margin	-81.5%	Revenue: 83138000 Open source Operating Cash Flow: -64690000 Open source Capital Expenditure: 3100000 Open source
20212021-12-31	Free cash flow margin	-52.8%	Revenue: 194134000 Open source Operating Cash Flow: -99154000 Open source Capital Expenditure: 3291000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -99.2M 2021

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Operating cash flow	-79840000	Operating Cash Flow: -79840000 Open source
20172017-12-31	Operating cash flow	-93213000	Operating Cash Flow: -93213000 Open source
20182018-12-31	Operating cash flow	-152576000	Operating Cash Flow: -152576000 Open source
20192019-12-31	Operating cash flow	-150430000	Operating Cash Flow: -150430000 Open source
20202020-12-31	Operating cash flow	-64690000	Operating Cash Flow: -64690000 Open source
20212021-12-31	Operating cash flow	-99154000	Operating Cash Flow: -99154000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -102.4M 2021

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Free cash flow	-84917000	Operating Cash Flow: -79840000 Open source Capital Expenditure: 5077000 Open source
20172017-12-31	Free cash flow	-109183000	Operating Cash Flow: -93213000 Open source Capital Expenditure: 15970000 Open source
20182018-12-31	Free cash flow	-183889000	Operating Cash Flow: -152576000 Open source Capital Expenditure: 31313000 Open source
20192019-12-31	Free cash flow	-160388000	Operating Cash Flow: -150430000 Open source Capital Expenditure: 9958000 Open source
20202020-12-31	Free cash flow	-67790000	Operating Cash Flow: -64690000 Open source Capital Expenditure: 3100000 Open source
20212021-12-31	Free cash flow	-102445000	Operating Cash Flow: -99154000 Open source Capital Expenditure: 3291000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

104% 2021

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Liabilities / assets	57.6%	Total Liabilities: 142910000 Open source Total Assets: 248254000 Open source
20172017-12-31	Liabilities / assets	53.3%	Total Liabilities: 154677000 Open source Total Assets: 290276000 Open source
20182018-12-31	Liabilities / assets	20.1%	Total Liabilities: 57238000 Open source Total Assets: 285044000 Open source
20192019-12-31	Liabilities / assets	63.1%	Total Liabilities: 285658000 Open source Total Assets: 452608000 Open source
20202020-12-31	Liabilities / assets	94%	Total Liabilities: 378077000 Open source Total Assets: 402045000 Open source
20212021-12-31	Liabilities / assets	104%	Total Liabilities: 448724000 Open source Total Assets: 431391000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

2.85× 2021

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Current assets / current liabilities	12.27×	Current Assets: 237690000 Open source Current Liabilities: 19371000 Open source
20172017-12-31	Current assets / current liabilities	10.09×	Current Assets: 254142000 Open source Current Liabilities: 25184000 Open source
20182018-12-31	Current assets / current liabilities	4.34×	Current Assets: 220175000 Open source Current Liabilities: 50784000 Open source
20192019-12-31	Current assets / current liabilities	4.5×	Current Assets: 376342000 Open source Current Liabilities: 83648000 Open source
20202020-12-31	Current assets / current liabilities	3.18×	Current Assets: 331755000 Open source Current Liabilities: 104472000 Open source
20212021-12-31	Current assets / current liabilities	2.85×	Current Assets: 355650000 Open source Current Liabilities: 124991000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2012 2012-01-01 – 2012-12-31	−USD 14.98 million Exact value Exact value: -14978000 USD 2012-01-01 – 2012-12-31: -14978000 USD Inspect Net Income Open source Share or cite Citation for Net Income · AERIE PHARMACEUTICALS INC · 2012-12-31 AERIE PHARMACEUTICALS INC (edgar:1337553) Net Income: -14978000 USD Concept: fundies:NetIncome Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1337553/explain?concept=fundies%3ANetIncome&period=2012-12-31&surface=latest&period_type=duration&start=2012-01-01&unit=USD&dimensions= Input fundies:NetIncome: -14978000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1337553/000162828015001188/aeri-20141231.xml#248336 Filing: 000162828015001188 The citation records this snapshot. The page link may show a newer release later.	−USD 14.97 million Exact value Exact value: -14968000 USD 2012-01-01 – 2012-12-31: -14968000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · AERIE PHARMACEUTICALS INC · 2012-12-31 AERIE PHARMACEUTICALS INC (edgar:1337553) Operating Cash Flow: -14968000 USD Concept: fundies:OperatingCashFlow Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1337553/explain?concept=fundies%3AOperatingCashFlow&period=2012-12-31&surface=latest&period_type=duration&start=2012-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -14968000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1337553/000162828015001188/aeri-20141231.xml#247580 Filing: 000162828015001188 The citation records this snapshot. The page link may show a newer release later.	USD 51,000 Exact value Exact value: 51000 USD 2012-01-01 – 2012-12-31: 51000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · AERIE PHARMACEUTICALS INC · 2012-12-31 AERIE PHARMACEUTICALS INC (edgar:1337553) Capital Expenditure: 51000 USD Concept: fundies:CapitalExpenditure Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1337553/explain?concept=fundies%3ACapitalExpenditure&period=2012-12-31&surface=latest&period_type=duration&start=2012-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 51000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1337553/000162828015001188/aeri-20141231.xml#261910 Filing: 000162828015001188 The citation records this snapshot. The page link may show a newer release later.	−USD 15.02 million Calculation and evidence -14968000 − 51000 USD Exact free cash flow: -15019000 USD 2012-01-01 – 2012-12-31: -14968000 USD · Inspect Operating Cash Flow · Source 2012-01-01 – 2012-12-31: 51000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · AERIE PHARMACEUTICALS INC · 2012-12-31 AERIE PHARMACEUTICALS INC (edgar:1337553) Free cash flow: -15019000 USD Concept: free-cash-flow Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1337553?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -14968000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1337553/000162828015001188/aeri-20141231.xml#247580 Filing: 000162828015001188 Input fundies:CapitalExpenditure: 51000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1337553/000162828015001188/aeri-20141231.xml#261910 Filing: 000162828015001188 The citation records this snapshot. The page link may show a newer release later.
2013 2013-01-01 – 2013-12-31	−USD 31.15 million Exact value Exact value: -31148000 USD 2013-01-01 – 2013-12-31: -31148000 USD Inspect Net Income Open source Share or cite Citation for Net Income · AERIE PHARMACEUTICALS INC · 2013-12-31 AERIE PHARMACEUTICALS INC (edgar:1337553) Net Income: -31148000 USD Concept: fundies:NetIncome Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1337553/explain?concept=fundies%3ANetIncome&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=USD&dimensions= Input fundies:NetIncome: -31148000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1337553/000162828016012101/aeri-20151231.xml#268634 Filing: 000162828016012101 The citation records this snapshot. The page link may show a newer release later.	−USD 16.45 million Exact value Exact value: -16448000 USD 2013-01-01 – 2013-12-31: -16448000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · AERIE PHARMACEUTICALS INC · 2013-12-31 AERIE PHARMACEUTICALS INC (edgar:1337553) Operating Cash Flow: -16448000 USD Concept: fundies:OperatingCashFlow Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1337553/explain?concept=fundies%3AOperatingCashFlow&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -16448000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1337553/000162828016012101/aeri-20151231.xml#267878 Filing: 000162828016012101 The citation records this snapshot. The page link may show a newer release later.	USD 63,000 Exact value Exact value: 63000 USD 2013-01-01 – 2013-12-31: 63000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · AERIE PHARMACEUTICALS INC · 2013-12-31 AERIE PHARMACEUTICALS INC (edgar:1337553) Capital Expenditure: 63000 USD Concept: fundies:CapitalExpenditure Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1337553/explain?concept=fundies%3ACapitalExpenditure&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 63000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1337553/000162828016012101/aeri-20151231.xml#280812 Filing: 000162828016012101 The citation records this snapshot. The page link may show a newer release later.	−USD 16.51 million Calculation and evidence -16448000 − 63000 USD Exact free cash flow: -16511000 USD 2013-01-01 – 2013-12-31: -16448000 USD · Inspect Operating Cash Flow · Source 2013-01-01 – 2013-12-31: 63000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · AERIE PHARMACEUTICALS INC · 2013-12-31 AERIE PHARMACEUTICALS INC (edgar:1337553) Free cash flow: -16511000 USD Concept: free-cash-flow Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1337553?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -16448000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1337553/000162828016012101/aeri-20151231.xml#267878 Filing: 000162828016012101 Input fundies:CapitalExpenditure: 63000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1337553/000162828016012101/aeri-20151231.xml#280812 Filing: 000162828016012101 The citation records this snapshot. The page link may show a newer release later.
2014 2014-01-01 – 2014-12-31	−USD 48.13 million Exact value Exact value: -48133000 USD 2014-01-01 – 2014-12-31: -48133000 USD Inspect Net Income Open source Share or cite Citation for Net Income · AERIE PHARMACEUTICALS INC · 2014-12-31 AERIE PHARMACEUTICALS INC (edgar:1337553) Net Income: -48133000 USD Concept: fundies:NetIncome Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1337553/explain?concept=fundies%3ANetIncome&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:NetIncome: -48133000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1337553/000162828017002421/aeri-20161231.xml#218245 Filing: 000162828017002421 The citation records this snapshot. The page link may show a newer release later.	−USD 33.73 million Exact value Exact value: -33726000 USD 2014-01-01 – 2014-12-31: -33726000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · AERIE PHARMACEUTICALS INC · 2014-12-31 AERIE PHARMACEUTICALS INC (edgar:1337553) Operating Cash Flow: -33726000 USD Concept: fundies:OperatingCashFlow Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1337553/explain?concept=fundies%3AOperatingCashFlow&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -33726000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1337553/000162828017002421/aeri-20161231.xml#217609 Filing: 000162828017002421 The citation records this snapshot. The page link may show a newer release later.	USD 181,000 Exact value Exact value: 181000 USD 2014-01-01 – 2014-12-31: 181000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · AERIE PHARMACEUTICALS INC · 2014-12-31 AERIE PHARMACEUTICALS INC (edgar:1337553) Capital Expenditure: 181000 USD Concept: fundies:CapitalExpenditure Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1337553/explain?concept=fundies%3ACapitalExpenditure&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 181000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1337553/000162828017002421/aeri-20161231.xml#232414 Filing: 000162828017002421 The citation records this snapshot. The page link may show a newer release later.	−USD 33.91 million Calculation and evidence -33726000 − 181000 USD Exact free cash flow: -33907000 USD 2014-01-01 – 2014-12-31: -33726000 USD · Inspect Operating Cash Flow · Source 2014-01-01 – 2014-12-31: 181000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · AERIE PHARMACEUTICALS INC · 2014-12-31 AERIE PHARMACEUTICALS INC (edgar:1337553) Free cash flow: -33907000 USD Concept: free-cash-flow Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1337553?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -33726000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1337553/000162828017002421/aeri-20161231.xml#217609 Filing: 000162828017002421 Input fundies:CapitalExpenditure: 181000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1337553/000162828017002421/aeri-20161231.xml#232414 Filing: 000162828017002421 The citation records this snapshot. The page link may show a newer release later.
2015 2015-01-01 – 2015-12-31	−USD 74.36 million Exact value Exact value: -74363000 USD 2015-01-01 – 2015-12-31: -74363000 USD Inspect Net Income Open source Share or cite Citation for Net Income · AERIE PHARMACEUTICALS INC · 2015-12-31 AERIE PHARMACEUTICALS INC (edgar:1337553) Net Income: -74363000 USD Concept: fundies:NetIncome Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1337553/explain?concept=fundies%3ANetIncome&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:NetIncome: -74363000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1337553/000162828018002651/aeri-20171231.xml#213954 Filing: 000162828018002651 The citation records this snapshot. The page link may show a newer release later.	−USD 55.75 million Exact value Exact value: -55746000 USD 2015-01-01 – 2015-12-31: -55746000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · AERIE PHARMACEUTICALS INC · 2015-12-31 AERIE PHARMACEUTICALS INC (edgar:1337553) Operating Cash Flow: -55746000 USD Concept: fundies:OperatingCashFlow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1337553/explain?concept=fundies%3AOperatingCashFlow&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -55746000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1337553/000162828018002651/aeri-20171231.xml#213318 Filing: 000162828018002651 The citation records this snapshot. The page link may show a newer release later.	USD 3.28 million Exact value Exact value: 3280000 USD 2015-01-01 – 2015-12-31: 3280000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · AERIE PHARMACEUTICALS INC · 2015-12-31 AERIE PHARMACEUTICALS INC (edgar:1337553) Capital Expenditure: 3280000 USD Concept: fundies:CapitalExpenditure Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1337553/explain?concept=fundies%3ACapitalExpenditure&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 3280000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1337553/000162828018002651/aeri-20171231.xml#227850 Filing: 000162828018002651 The citation records this snapshot. The page link may show a newer release later.	−USD 59.03 million Calculation and evidence -55746000 − 3280000 USD Exact free cash flow: -59026000 USD 2015-01-01 – 2015-12-31: -55746000 USD · Inspect Operating Cash Flow · Source 2015-01-01 – 2015-12-31: 3280000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · AERIE PHARMACEUTICALS INC · 2015-12-31 AERIE PHARMACEUTICALS INC (edgar:1337553) Free cash flow: -59026000 USD Concept: free-cash-flow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1337553?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -55746000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1337553/000162828018002651/aeri-20171231.xml#213318 Filing: 000162828018002651 Input fundies:CapitalExpenditure: 3280000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1337553/000162828018002651/aeri-20171231.xml#227850 Filing: 000162828018002651 The citation records this snapshot. The page link may show a newer release later.
2016 2016-01-01 – 2016-12-31	−USD 99.06 million Exact value Exact value: -99059000 USD 2016-01-01 – 2016-12-31: -99059000 USD Inspect Net Income Open source Share or cite Citation for Net Income · AERIE PHARMACEUTICALS INC · 2016-12-31 AERIE PHARMACEUTICALS INC (edgar:1337553) Net Income: -99059000 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1337553/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: -99059000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1337553/000162828019002369/aeri-20181231.xml#229079 Filing: 000162828019002369 The citation records this snapshot. The page link may show a newer release later.	−USD 79.84 million Exact value Exact value: -79840000 USD 2016-01-01 – 2016-12-31: -79840000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · AERIE PHARMACEUTICALS INC · 2016-12-31 AERIE PHARMACEUTICALS INC (edgar:1337553) Operating Cash Flow: -79840000 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1337553/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -79840000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1337553/000162828019002369/aeri-20181231.xml#228442 Filing: 000162828019002369 The citation records this snapshot. The page link may show a newer release later.	USD 5.08 million Exact value Exact value: 5077000 USD 2016-01-01 – 2016-12-31: 5077000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · AERIE PHARMACEUTICALS INC · 2016-12-31 AERIE PHARMACEUTICALS INC (edgar:1337553) Capital Expenditure: 5077000 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1337553/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 5077000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1337553/000162828019002369/aeri-20181231.xml#240612 Filing: 000162828019002369 The citation records this snapshot. The page link may show a newer release later.	−USD 84.92 million Calculation and evidence -79840000 − 5077000 USD Exact free cash flow: -84917000 USD 2016-01-01 – 2016-12-31: -79840000 USD · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 5077000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · AERIE PHARMACEUTICALS INC · 2016-12-31 AERIE PHARMACEUTICALS INC (edgar:1337553) Free cash flow: -84917000 USD Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1337553?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -79840000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1337553/000162828019002369/aeri-20181231.xml#228442 Filing: 000162828019002369 Input fundies:CapitalExpenditure: 5077000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1337553/000162828019002369/aeri-20181231.xml#240612 Filing: 000162828019002369 The citation records this snapshot. The page link may show a newer release later.
2017 2017-01-01 – 2017-12-31	−USD 145.11 million Exact value Exact value: -145105000 USD 2017-01-01 – 2017-12-31: -145105000 USD Inspect Net Income Open source Share or cite Citation for Net Income · AERIE PHARMACEUTICALS INC · 2017-12-31 AERIE PHARMACEUTICALS INC (edgar:1337553) Net Income: -145105000 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1337553/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -145105000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1337553/000162828020002027/aeri-1231201910xk.htm#1805895 Filing: 000162828020002027 The citation records this snapshot. The page link may show a newer release later.	−USD 93.21 million Exact value Exact value: -93213000 USD 2017-01-01 – 2017-12-31: -93213000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · AERIE PHARMACEUTICALS INC · 2017-12-31 AERIE PHARMACEUTICALS INC (edgar:1337553) Operating Cash Flow: -93213000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1337553/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -93213000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1337553/000162828020002027/aeri-1231201910xk.htm#1841266 Filing: 000162828020002027 The citation records this snapshot. The page link may show a newer release later.	USD 15.97 million Exact value Exact value: 15970000 USD 2017-01-01 – 2017-12-31: 15970000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · AERIE PHARMACEUTICALS INC · 2017-12-31 AERIE PHARMACEUTICALS INC (edgar:1337553) Capital Expenditure: 15970000 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1337553/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 15970000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1337553/000162828020002027/aeri-1231201910xk.htm#1854172 Filing: 000162828020002027 The citation records this snapshot. The page link may show a newer release later.	−USD 109.18 million Calculation and evidence -93213000 − 15970000 USD Exact free cash flow: -109183000 USD 2017-01-01 – 2017-12-31: -93213000 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 15970000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · AERIE PHARMACEUTICALS INC · 2017-12-31 AERIE PHARMACEUTICALS INC (edgar:1337553) Free cash flow: -109183000 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1337553?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -93213000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1337553/000162828020002027/aeri-1231201910xk.htm#1841266 Filing: 000162828020002027 Input fundies:CapitalExpenditure: 15970000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1337553/000162828020002027/aeri-1231201910xk.htm#1854172 Filing: 000162828020002027 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	−USD 232.57 million Exact value Exact value: -232569000 USD 2018-01-01 – 2018-12-31: -232569000 USD Inspect Net Income Open source Share or cite Citation for Net Income · AERIE PHARMACEUTICALS INC · 2018-12-31 AERIE PHARMACEUTICALS INC (edgar:1337553) Net Income: -232569000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1337553/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -232569000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1337553/000162828021003345/aeri-20201231.htm#1835579 Filing: 000162828021003345 The citation records this snapshot. The page link may show a newer release later.	−USD 152.58 million Exact value Exact value: -152576000 USD 2018-01-01 – 2018-12-31: -152576000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · AERIE PHARMACEUTICALS INC · 2018-12-31 AERIE PHARMACEUTICALS INC (edgar:1337553) Operating Cash Flow: -152576000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1337553/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -152576000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1337553/000162828021003345/aeri-20201231.htm#1877649 Filing: 000162828021003345 The citation records this snapshot. The page link may show a newer release later.	USD 31.31 million Exact value Exact value: 31313000 USD 2018-01-01 – 2018-12-31: 31313000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · AERIE PHARMACEUTICALS INC · 2018-12-31 AERIE PHARMACEUTICALS INC (edgar:1337553) Capital Expenditure: 31313000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1337553/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 31313000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1337553/000162828021003345/aeri-20201231.htm#1890939 Filing: 000162828021003345 The citation records this snapshot. The page link may show a newer release later.	−USD 183.89 million Calculation and evidence -152576000 − 31313000 USD Exact free cash flow: -183889000 USD 2018-01-01 – 2018-12-31: -152576000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 31313000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · AERIE PHARMACEUTICALS INC · 2018-12-31 AERIE PHARMACEUTICALS INC (edgar:1337553) Free cash flow: -183889000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1337553?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -152576000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1337553/000162828021003345/aeri-20201231.htm#1877649 Filing: 000162828021003345 Input fundies:CapitalExpenditure: 31313000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1337553/000162828021003345/aeri-20201231.htm#1890939 Filing: 000162828021003345 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 199.58 million Exact value Exact value: -199581000 USD 2019-01-01 – 2019-12-31: -199581000 USD Inspect Net Income Open source Share or cite Citation for Net Income · AERIE PHARMACEUTICALS INC · 2019-12-31 AERIE PHARMACEUTICALS INC (edgar:1337553) Net Income: -199581000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1337553/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -199581000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1337553/000133755322000013/aeri-20211231.htm#1767578 Filing: 000133755322000013 The citation records this snapshot. The page link may show a newer release later.	−USD 150.43 million Exact value Exact value: -150430000 USD 2019-01-01 – 2019-12-31: -150430000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · AERIE PHARMACEUTICALS INC · 2019-12-31 AERIE PHARMACEUTICALS INC (edgar:1337553) Operating Cash Flow: -150430000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1337553/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -150430000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1337553/000133755322000013/aeri-20211231.htm#1810662 Filing: 000133755322000013 The citation records this snapshot. The page link may show a newer release later.	USD 9.96 million Exact value Exact value: 9958000 USD 2019-01-01 – 2019-12-31: 9958000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · AERIE PHARMACEUTICALS INC · 2019-12-31 AERIE PHARMACEUTICALS INC (edgar:1337553) Capital Expenditure: 9958000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1337553/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 9958000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1337553/000133755322000013/aeri-20211231.htm#1823977 Filing: 000133755322000013 The citation records this snapshot. The page link may show a newer release later.	−USD 160.39 million Calculation and evidence -150430000 − 9958000 USD Exact free cash flow: -160388000 USD 2019-01-01 – 2019-12-31: -150430000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 9958000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · AERIE PHARMACEUTICALS INC · 2019-12-31 AERIE PHARMACEUTICALS INC (edgar:1337553) Free cash flow: -160388000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1337553?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -150430000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1337553/000133755322000013/aeri-20211231.htm#1810662 Filing: 000133755322000013 Input fundies:CapitalExpenditure: 9958000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1337553/000133755322000013/aeri-20211231.htm#1823977 Filing: 000133755322000013 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 183.1 million Exact value Exact value: -183101000 USD 2020-01-01 – 2020-12-31: -183101000 USD Inspect Net Income Open source Share or cite Citation for Net Income · AERIE PHARMACEUTICALS INC · 2020-12-31 AERIE PHARMACEUTICALS INC (edgar:1337553) Net Income: -183101000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1337553/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -183101000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1337553/000133755322000013/aeri-20211231.htm#1766408 Filing: 000133755322000013 The citation records this snapshot. The page link may show a newer release later.	−USD 64.69 million Exact value Exact value: -64690000 USD 2020-01-01 – 2020-12-31: -64690000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · AERIE PHARMACEUTICALS INC · 2020-12-31 AERIE PHARMACEUTICALS INC (edgar:1337553) Operating Cash Flow: -64690000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1337553/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -64690000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1337553/000133755322000013/aeri-20211231.htm#1809611 Filing: 000133755322000013 The citation records this snapshot. The page link may show a newer release later.	USD 3.1 million Exact value Exact value: 3100000 USD 2020-01-01 – 2020-12-31: 3100000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · AERIE PHARMACEUTICALS INC · 2020-12-31 AERIE PHARMACEUTICALS INC (edgar:1337553) Capital Expenditure: 3100000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1337553/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 3100000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1337553/000133755322000013/aeri-20211231.htm#1822994 Filing: 000133755322000013 The citation records this snapshot. The page link may show a newer release later.	−USD 67.79 million Calculation and evidence -64690000 − 3100000 USD Exact free cash flow: -67790000 USD 2020-01-01 – 2020-12-31: -64690000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 3100000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · AERIE PHARMACEUTICALS INC · 2020-12-31 AERIE PHARMACEUTICALS INC (edgar:1337553) Free cash flow: -67790000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1337553?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -64690000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1337553/000133755322000013/aeri-20211231.htm#1809611 Filing: 000133755322000013 Input fundies:CapitalExpenditure: 3100000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1337553/000133755322000013/aeri-20211231.htm#1822994 Filing: 000133755322000013 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 74.81 million Exact value Exact value: -74810000 USD 2021-01-01 – 2021-12-31: -74810000 USD Inspect Net Income Open source Share or cite Citation for Net Income · AERIE PHARMACEUTICALS INC · 2021-12-31 AERIE PHARMACEUTICALS INC (edgar:1337553) Net Income: -74810000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1337553/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -74810000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1337553/000133755322000013/aeri-20211231.htm#1764693 Filing: 000133755322000013 The citation records this snapshot. The page link may show a newer release later.	−USD 99.15 million Exact value Exact value: -99154000 USD 2021-01-01 – 2021-12-31: -99154000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · AERIE PHARMACEUTICALS INC · 2021-12-31 AERIE PHARMACEUTICALS INC (edgar:1337553) Operating Cash Flow: -99154000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1337553/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -99154000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1337553/000133755322000013/aeri-20211231.htm#1808560 Filing: 000133755322000013 The citation records this snapshot. The page link may show a newer release later.	USD 3.29 million Exact value Exact value: 3291000 USD 2021-01-01 – 2021-12-31: 3291000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · AERIE PHARMACEUTICALS INC · 2021-12-31 AERIE PHARMACEUTICALS INC (edgar:1337553) Capital Expenditure: 3291000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1337553/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 3291000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1337553/000133755322000013/aeri-20211231.htm#1822011 Filing: 000133755322000013 The citation records this snapshot. The page link may show a newer release later.	−USD 102.45 million Calculation and evidence -99154000 − 3291000 USD Exact free cash flow: -102445000 USD 2021-01-01 – 2021-12-31: -99154000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 3291000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · AERIE PHARMACEUTICALS INC · 2021-12-31 AERIE PHARMACEUTICALS INC (edgar:1337553) Free cash flow: -102445000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T23:23:14Z Snapshot: ca0e640291d283e31cd085dc5f031d4808aa3fcec275282fa6d28a8b9cdc6dad Dimensions: Consolidated View: https://fundies.io/companies/edgar/1337553?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -99154000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1337553/000133755322000013/aeri-20211231.htm#1808560 Filing: 000133755322000013 Input fundies:CapitalExpenditure: 3291000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1337553/000133755322000013/aeri-20211231.htm#1822011 Filing: 000133755322000013 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

174 filings · 2,656 latest values · 2,656 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001337553, 1337553, AERI, edgar:1337553

Also known as AERIE PHARMACEUTICALS INC, Aerie Pharmaceuticals, Inc.

AERIE PHARMACEUTICALS INC

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2021 2021-01-01 – 2021-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation